Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales

Wave Life Sciences stock has fallen 68.4% year to date, yet on broad valuation checks it still screens as expensive rather than a clear bargain. Recent corporate changes, including the move of its parent company to Delaware, add an extra layer of context for investors trying to assess what the current share price really reflects.

• Year to date, Wave Life Sciences shares are down 68.4%, which puts recent trading firmly in loss territory for existing holders.
• The recent redomiciliation of the parent company to Delaware may support longer term access to U.S. capital markets, while the share price slide highlights ongoing risk that investor confidence in the business model and funding path remains fragile.
• On Simply Wall St's valuation checks, Wave Life Sciences is viewed as expensive, with the stock passing 0 out of 6 checks. This suggests it does not currently stand out as a clear bargain on traditional metrics 0/6 valuation score.

The issue now is whether the current share price already reflects these pressures on Wave Life Sciences or if investors are still paying too much for the risks involved.

Find out why Wave Life Sciences' -40.3% return over the last year is lagging behind its peers.

Has Wave Life Sciences Run Too Far on Sales?

P/S is often more helpful than P/E for a company like Wave Life Sciences that is focused on research and does not yet have a stable earnings base.

Wave Life Sciences currently trades on a P/S of 15.2x, compared with an industry average of 5.0x and a peer average of 2.9x. Even after a sharp share price decline this year, investors are still paying a much higher price for each dollar of reported revenue than is typical in the Pharmaceuticals industry.

The modelled fair P/S ratio for Wave Life Sciences is 0.7x, which is far below the current 15.2x. The framework is heavily penalising the company for its ongoing losses and risk profile, so that gap is more a warning flag that the stock screens as very expensive on this metric rather than a precise target. Despite the recent redomiciliation to Delaware, which was aimed at supporting access to U.S. capital markets, the current P/S suggests that a lot is already being asked of Wave Life Sciences at today’s share price.

On the preferred P/S multiple, Wave Life Sciences stock currently appears overvalued.

See what the numbers say about this price — find out in our valuation breakdown.

The Wave Life Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Wave Life Sciences act as the link between the current valuation puzzle and the future assumptions that could justify a higher or lower share price, by spelling out what would need to happen to revenue growth, margins and eventual earnings. Each Narrative ties a fair value to a specific storyline about Wave Life Sciences' potential catalysts and risks so you can track over time which version of events appears to be taking shape.

One of the top community narratives on Wave Life Sciences: 74% undervalued

"The expansion and clinical validation of Wave's proprietary RNA editing and siRNA platforms, including the emergence of new wholly-owned pipeline candidates for both rare and prevalent diseases..."

Read one of the top narratives on Wave Life Sciences

Do you think there's more to the story for Wave Life Sciences? Head over to our Community to see what others are saying!

The Bottom Line

Wave Life Sciences still screens as overvalued on the preferred P/S multiple, even after a year to date share price drop and a wide gap between its current ratio and the modelled fair level. That disconnect reflects how much the market is already assuming about future revenue and execution despite ongoing losses and funding risk. With the broader valuation checks looking weak, the key question is whether Wave Life Sciences can eventually grow into this premium multiple or whether the current pricing proves too optimistic for the risk involved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com